9 Lymphoma Clinical Trials in New Brunswick, NJ (2026)

Q: How do I join a clinical trial in New Brunswick?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the New Brunswick research site will contact you.

Recruiting Lymphoma Studies in New Brunswick

NCT06072131Recruiting

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for...

New Brunswick, NJPHASE3504 participantsAcrotech Biopharma Inc.

View Study Details

NCT06564038Recruiting

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

The purpose of this study is to assess the safety and efficacy of AZD0486 administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies....

New Brunswick, NJPHASE1408 participantsAstraZeneca

View Study Details

NCT06393738Recruiting

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R...

New Brunswick, NJPHASE1255 participantsArvinas Inc.

View Study Details

NCT05685173Recruiting

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

This study is researching an experimental drug called REGN5837 in combination with another drug, odronextamab (called "study drug\[s\]"), in patients with relapsed or refractory aggressive B-cell Non-...

New Brunswick, NJPHASE1107 participantsRegeneron Pharmaceuticals

View Study Details

NCT04998669Recruiting

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

The purpose of this research is to see if Loncastuximab Tesirine in combination with Rituximab will result in higher complete response rate when given to treat follicular lymphoma....

New Brunswick, NJPHASE2100 participantsJuan P. Alderuccio, MD

View Study Details

NCT05607420Recruiting

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of t...

New Brunswick, NJPHASE180 participantsCellectis S.A.

View Study Details

NCT07015242Recruiting

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central N...

New Brunswick, NJPHASE265 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT04792502Recruiting

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

BrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL. All patients will be assigned the same initial treatment plan, modifi...

New Brunswick, NJPHASE252 participantsBrown University

View Study Details

NCT06544265Recruiting

SynKIR-310 for Relapsed/Refractory B-NHL

This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refrac...

New Brunswick, NJPHASE136 participantsVerismo Therapeutics

View Study Details

About Lymphoma Clinical Trials in New Brunswick

Lymphoma is a cancer of the lymphatic system that affects infection-fighting cells called lymphocytes. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma. Treatment often includes chemotherapy, radiation, immunotherapy, and in some cases stem cell transplant.

There are currently 9 lymphoma clinical trials recruiting participants in New Brunswick, NJ. These studies are seeking a combined 1,607 participants. Research is being sponsored by Acrotech Biopharma Inc., AstraZeneca, Arvinas Inc. and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lymphoma Clinical Trials in New Brunswick — FAQ

Are there lymphoma clinical trials in New Brunswick?

Yes, there are 9 lymphoma clinical trials currently recruiting in New Brunswick, NJ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New Brunswick?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New Brunswick research site will contact you about next steps.

Are clinical trials in New Brunswick free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New Brunswick studies also compensate for your time and travel.

What lymphoma treatments are being tested?

The 9 active trials in New Brunswick are testing new therapies including novel drugs, biologics, and treatment approaches for lymphoma.

Data updated July 19, 2026 from ClinicalTrials.gov